HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (13) Citing Articles via Google Scholar Google Scholar Articles by Kim, I. K. Articles by Miller, J. W. Search for Related Content PubMed PubMed Citation Articles by Kim, I. K. Articles by Miller, J. W.

Effect of Intravitreal Injection of Ranibizumab in Combination with Verteporfin PDT on Normal Primate Retina and Choroid

¹From the Angiogenesis and Laser Laboratory, Retina Research Institute, Department of Ophthalmology, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts; ²Department of Ophthalmology, Boston University School of Medicine, Boston, Massachusetts; ³BioMarin Pharmaceuticals, Novato, California; and the ⁴Department of Safety Assessment, Genentech, Inc., South San Francisco, California.

PURPOSE. To evaluate the effect of intravitreal injection of a monoclonal antibody fragment (ranibizumab, also known as rhuFab V2 and Lucentis; Genentech, S. San Francisco, CA) directed against vascular endothelial growth factor (VEGF) in combination with verteporfin photodynamic therapy (PDT) on normal primate retina and choroid.

METHODS. Eight cynomolgus monkeys were treated with intravitreal ranibizumab in one eye and placebo in the other, alternating with verteporfin PDT in both eyes on a weekly basis for 6 to 7 weeks. Treatment effects were evaluated by color fundus photography, fluorescein angiography, and light and electron microscopy.

RESULTS. Over the course of the study, increasing retinal pigment epithelial changes, with corresponding window defects, developed in both eyes of all animals on fluorescein angiography over the course of the study. No complications attributable to the intravitreal injection of ranibizumab were observed. Histologic analysis revealed a similar reduction in choriocapillaris density in the irradiated area of eyes treated with PDT alone compared with those that received combination treatment.

CONCLUSIONS. In this limited study of normal monkey eyes, no severe adverse effects from the combination of intravitreal ranibizumab and verteporfin PDT were demonstrated compared with PDT alone.

This article has been cited by other articles:

				Y. Hu, T. Zhang, J. Wu, Y. Li, X. Lu, F. Qian, Z. Yin, and Z. Ma Autologous Transplantation of RPE with Partial-Thickness Choroid after Mechanical Debridement of Bruch Membrane in the Rabbit Invest. Ophthalmol. Vis. Sci., July 1, 2008; 49(7): 3185 - 3192. [Abstract] [Full Text] [PDF]

				S. R. Sadda, S. Joeres, Z. Wu, P. Updike, P. Romano, A. T. Collins, and A. C. Walsh Error Correction and Quantitative Subanalysis of Optical Coherence Tomography Data Using Computer-Assisted Grading Invest. Ophthalmol. Vis. Sci., February 1, 2007; 48(2): 839 - 848. [Abstract] [Full Text] [PDF]